Roy Doumani - Kite Pharma Independent Director
Director
Mr. Roy Doumani is Independent Director of the Company. Mr. Doumani is a professor at the David Geffen School of Medicine at UCLA and Executive Director of the UCLA Business of Science Center . Since 2005, he has served as CoChairman of the Zhejiang California NanoSystems Institute in the Peoples Republic of China and is a shareholder and Director of the first joint venture bank in the PRC, Xiamen International Bank . Mr. Doumani was involved with numerous financial institutions Director of First Los Angeles Bank, Chairman of First Interstate Bank of Hawaii, Chairman of World Trade Bank in Los Angeles, Executive Director of HonFed Bank, and is one of the founders of Agensys, Inc. He is presently Chairman of Neural Analytics, Inc. . Mr. Doumani graduated from UCLA with a degree in Business and Finance and received a law degree from the University of Southern California. since 2011.
| Age | 80 |
| Tenure | 13 years |
| Phone | 310 824-9999 |
| Web | www.kitepharma.com |
Kite Pharma Management Efficiency
Kite Pharma's management efficiency ratios could be used to measure how well Kite Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Bailey | Micron Technology | 60 | |
| Steven Gomo | Micron Technology | 66 | |
| Zhongxi Li | Taiwan Semiconductor Manufactur | N/A | |
| Shay David | Kaltura | 51 | |
| Charles Bland | MACOM Technology Solutions | 69 | |
| Stan Shih | Taiwan Semiconductor Manufactur | N/A | |
| William Hurley | IPG Photonics | 71 | |
| Meiling Chen | Taiwan Semiconductor Manufactur | N/A | |
| Ivan Donaldson | Micron Technology | N/A | |
| Warren East | Micron Technology | 52 | |
| Mercedes Johnson | Micron Technology | 63 | |
| Catherine Lego | IPG Photonics | 60 | |
| Zhenrong Shi | Taiwan Semiconductor Manufactur | N/A | |
| Gil Lunsen | MACOM Technology Solutions | 75 | |
| Richard Beyer | Micron Technology | 69 | |
| Patrick Byrne | Micron Technology | 57 | |
| Lawrence Mondry | Micron Technology | 56 | |
| Michael Splinter | Taiwan Semiconductor Manufactur | 70 | |
| Peter Chung | MACOM Technology Solutions | 50 | |
| Wade Meyercord | Microchip Technology | 76 | |
| Ivanhoe Donaldson | Micron Technology | N/A | |
Management Performance
| Return On Equity | -0.0063 | |||
| Return On Asset | -1.0E-4 |
Kite Pharma Leadership Team
Elected by the shareholders, the Kite Pharma's board of directors comprises two types of representatives: Kite Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kite. The board's role is to monitor Kite Pharma's management team and ensure that shareholders' interests are well served. Kite Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kite Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ran Nussbaum, Independent Director | ||
| Jonathan Peacock, Independent Director | ||
| Shawn Tomasello, Chief Commercial Officer | ||
| Jian Irish, Senior Vice President - Supply Chain | ||
| Cynthia Butitta, CFO and COO | ||
| Franz Humer, Director | ||
| Timothy Moore, Executive Vice President - Technical Operations | ||
| Jeffrey Wiezorek, Vice President - Clinical Development | ||
| Ian Clark, Independent Director | ||
| Steven Ruchefsky, Independent Director | ||
| Joshua Kazam, Director | ||
| Helen Kim, Executive Vice President - Business Development | ||
| Helen MBA, Executive VP of Bus. Devel. | ||
| David Bonderman, Lead Independent Director | ||
| David Chang, Executive Vice President - Research and Development, Chief Medical Officer | ||
| Arie Belldegrun, Executive Chairman of the Board and Presidentident, CEO, Founder | ||
| Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations | ||
| Owen Witte, Director | ||
| Paul Jenkinson, CFO | ||
| Marc Better, VP of Translation Medicine | ||
| Farah Champsi, Independent Director | ||
| Roy Doumani, Independent Director | ||
| Rizwana Sproule, Vice President - Regulatory Affairs | ||
| Margo Roberts, Chief Scientific Officer |
Kite Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kite Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0063 | |||
| Return On Asset | -1.0E-4 | |||
| Current Valuation | 9.5 B | |||
| Shares Outstanding | 57.36 M | |||
| Shares Owned By Insiders | 6.93 % | |||
| Shares Owned By Institutions | 90.47 % | |||
| Number Of Shares Shorted | 8.08 M | |||
| Price To Earning | (25.85) X | |||
| Price To Book | 14.47 X | |||
| Price To Sales | 320.94 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kite Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kite Pharma's short interest history, or implied volatility extrapolated from Kite Pharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Kite Stock
If you are still planning to invest in Kite Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kite Pharma's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |